Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

shutterstock 556378990

Interview 15 May 2017

Meet the CEO developing the Next Generation of Antibody Therapeutics

Crescendo Biologics has positioned itself as the successor of Cambridge Antibody Technology and a new rival to Morphosys. We interviewed CEO Peter Pack. Peter Pack started working in life science 25 years ago — “quite a long time ago,” he laughs. “I’m an old guy now.” Now the CEO of Crescendo Biologics, whose Humabody platform […]

May 15, 2017 - 8 minutesmins - By Evelyn Warner

Rebecca Harris Symbiosis Invisible You Microbiome

News and Trends 13 May 2017

Visualizing the Microbiome through Handmade Embroidery

Rebecca Harris is a British artist that uses handmade embroidery to visually communicate the huge diversity of microbes that form part of our bodies. Trillions of microbes live on us and inside us. “Microbes are essential for our well-being and development. The microbes stimulate and develop the immune response, and they detoxify harmful carcinogenic compounds in our […]

May 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Cardior Pharmaceuticals fundraising

News and Trends 12 May 2017

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […]

May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

fossil proteins virus resistance granada

News and Trends 12 May 2017

Resurrected Proteins could be New Weapon against Crop Viruses

Researchers from Spain have succeeded in expressing a 4 billion year-old enzyme in a present-day E. coli. It’s similar enough to the modern version to work, but different enough to dupe viruses. A new way to create virus resistance in crops? In a lab at the University of Granada, Spain, that specializes in reconstructing ancient gene sequences, researchers have […]

May 12, 2017 - 3 minutesmins - By Denise Neves Gameiro

shutterstock 491203939

News and Trends 12 May 2017

UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval

UPDATE (12/05/2017): Newron has received €11.3M as a milestone payment for the approval from its partner, Zambon, which has the rights to commercialise Xadago globally. Originally published on 21/04/2017 Newron, an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World […]

May 12, 2017 - 2 minutesmins - By Evelyn Warner

Celyad heart failure cell therapy C Cure

News and Trends 11 May 2017

Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy

Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient’s own stem cells. Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic […]

May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

ADVERTISEMENT

raffi thumbnail youtube 720

Interview 11 May 2017

Video: Meet the CEO developing Gene Therapy without Viral Vectors

Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company’s CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris and has set itself the mission of enhancing current treatment options in the field of ophthalmology. The biotech has developed a new gene therapeutic approach that […]

May 11, 2017 - 2 minutesmins - By Melanie De Almeida

Study HIV Life Expectancy

News and Trends 11 May 2017

HIV Treatment Development Extends Life Expectancy by 10 Years

According to a new study, the life expectancy of 20-year-olds starting HIV treatment has increased by a decade in the EU and North America. A massive new study from the UK was published today in The Lancet HIV. The study tracked how many HIV patients died during the first three years of HIV treatment, their cause […]

May 11, 2017 - 3 minutesmins - By Melanie De Almeida

shutterstock 620087714

News and Trends 10 May 2017

Oxford Synbio Startup with Eyes on Therapeutics gets hold of CRISPR

Synbio startup Oxford Genetics has licensed CRISPR from Emmanuelle Charpentier’s company, ERS Genomics, to boost its platform. Synthetic biology has so far remained on the fringe of biotech, but one company, Oxford Genetics, is demonstrating its use in therapeutics. To bolster its efforts, the startup has secured a nonexclusive license from ERS Genomics, which represents […]

May 10, 2017 - 2 minutesmins - By Evelyn Warner

Roche tecentriq bladder cancer fail

News and Trends 10 May 2017

Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials

Roche’s drug tecentriq just failed a late-stage Phase III study in bladder cancer, raising questions about its future as an anticipated blockbuster. Roche and Genentech have been pushing their checkpoint inhibitor tecentriq onto the market last year, going for a number of different indications including bladder cancer and non-small cell lung cancer (NSCLC). After the FDA handed out accelerated approval in May 2016, […]

May 10, 2017 - 3 minutesmins - By Melanie De Almeida

linda summerton thumbnail youtube 720

Interview 10 May 2017

Video: Meet the CEO fighting Cancer with Mycobacteria

Clara talked to Linda Summerton, CEO of Immodulon Therapeutics, about the company’s project of applying the microbiome to immuno-oncology. As R&D efforts in the microbiome gain traction, Clara talked to the head of one of the most valuable companies in the UK, Immodulon Therapeutics. When asked about Forbes’ valuation of her company at £400M, Linda Summerton laughed, “That’s […]

May 10, 2017 - 3 minutesmins - By Evelyn Warner

In Depth 10 May 2017

Incentivizing Charity: A New Way to Fund Cancer Research

Here’s what we learned from a lecture by finance guru Roger Stein on a new cancer research funding model at the Charité BIH Entrepreneurship Summit in Berlin. “I’m not a scientist. I can’t build a drug. I’m never going to have enough money to fund even one of those [clinical] trials. But…all of us together […]

May 10, 2017 - 4 minutesmins - By Evelyn Warner

ADVERTISEMENT